PRENOSTICS
LIVE

Serial Number

98780004

Owner

PRENOSTICS LIMITED

Attorney

Ben Natter

Filing Date

Oct 1, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PRENOSTICS Trademark

Serial Number: 98780004 • Registration: 8091382

PRENOSTICS is a trademark filed by PRENOSTICS LIMITED on October 1, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PRENOSTICS LIMITED (3 trademarks)

LYNTON HOUSE, 53 WOODGREEN, WITNEY,
OXFORDSHIRE, ENGLAND, OX28 1DB , GB

Entity Type: 99

RNA GUARDIAN LTD (3 trademarks)

Lynton House, 53 Woodgreen, Witney
England Oxfordshire OX281DB , GB

Entity Type: 99

Trademark Details

Filing Date

October 1, 2024

Registration Date

January 6, 2026

Published for Opposition

November 18, 2025

Goods & Services

Medical diagnostic services; Medical testing for diagnostic or treatment purposes; Medical analysis services for the diagnosis of cancer; Remote monitoring of medical data for medical diagnosis and treatment; Medical analysis services for cancer diagnosis and prognosis; Medical testing services relating to the diagnosis and treatment of disease; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Performing diagnosis of diseases; Prostate cancer screening services; Breast cancer screening services; Lung cancer screening services; Testicular cancer screening services; Cervical cancer screening services; Bowel cancer screening; Medical services for the treatment of skin cancer; RNA or DNA analysis for cancer diagnosis and prognosis; Providing cancer screening services; Analysis of human tissues for medical treatment; Advisory services relating to the treatment of degenerative diseases; Analysis of human serum for medical treatment; Health care; Health risk assessment; Providing health advice for elderly people; all of the aforesaid services provided in relation to cancer diagnosis, treatment and therapy

Medical diagnostic reagents; Clinical medical diagnostic reagents; Reagents for use in diagnostic tests for medical purposes; Medical diagnostic reagents and assays for testing of body fluids; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical use; Reagents and media for medical and veterinary diagnostic purposes; Diagnostic testing materials being diagnostic reagents for medical use; Chemical diagnostic reagents for medical use; Diagnostic chemical reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Indicators for medical diagnosis, namely, medical diagnostic reagents; Reagents for use in medical genetic testing; Diagnostic preparations for medical purposes; Diagnostic reagents for medicinal use; Reagents for use with analyzers for medical use; Diagnostic agents for medical use; Radio-isotope markers for therapeutic or diagnostic use; Biopharmaceuticals preparations for the treatment of cancer; Compounds for treating cancer, namely, liquid compounds for medical or therapeutic use; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for the treatment of tumours; Pharmaceutical preparations for the prevention of tumours; Anti-cancer drugs being pharmaceutical preparations for the prevention of cancer; Chemotherapeutics; Pharmaceutical preparations for the treatment of diseases of the metabolic system; Pharmaceutical preparations for suppressing tumors; Tumor suppressing agents; Protein synthesis inhibitors, namely, pharmaceutical substances for slowing cell growth for medical purposes; Neoantigens, namely, antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Diagnostic radiopharmaceutical preparations; Clinical medical reagents; all of the aforesaid goods provided in relation to cancer diagnosis, treatment and therapy

Tools for medical diagnostics, namely, MRI apparatus for medical purposes, X-ray CT scanners, Biopsy instruments; Diagnostic testing instruments for use in immunoassay procedure for medical diagnosis purposes; Testing probes for medical diagnostic purposes; Diagnostic, examination, and monitoring equipment, namely, MRI apparatus for medical purposes, X-ray CT scanners, Biopsy instruments; Medical diagnostic testing apparatus for use in immunoassay procedures; Medical diagnostic instruments, namely, Biopsy instruments; Testing instruments for medical diagnostic purposes, namely, MRI apparatus for medical purposes, X-ray CT scanners, Biopsy instruments; Nuclear medicine diagnostic imaging apparatus; Spectrum analyzers in the nature of cancer and pre-cancerous cells and RNA and DNA analysis for use in medical diagnosis; Diagnostic imaging apparatus for medical use; Diagnostic instruments for medical use; Diagnostic apparatus for cancer and pre-cancerous cells and RNA and DNA analysis for medical purposes; Medical diagnostic apparatus cancer and pre-cancerous cells and RNA and DNA analysis for medical purposes; Medical apparatus for the treatment of cancer; Medical apparatus for tumour diagnosis; all of the aforesaid goods provided in relation to cancer diagnosis, treatment and therapy

In-vivo diagnostic reagents for scientific use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Diagnostic reagents for scientific or research use; all of the aforesaid goods provided in relation to cancer diagnosis, treatment and therapy

Product design and development of medical technology; Computer diagnostic services; Product development of medical diagnostic apparatus; Research and development in the field of diagnostic preparations for medical purposes; Scientific and technological services, namely, research and design in the field of cancer, pre-cancerous cells, and RNA and DNA analysis; ; industrial analysis in the nature of cancer, pre-cancerous cells, and RNA and DNA analysis and product research services; design and development of computer hardware and software; design and development of computer hardware and software, in particular computer programs; scientific research for medical purposes, in particular research and development in the field of human medical and veterinary medical diagnostics and therapy; Medical research; Scientific research for medical purposes in the field of cancer, pre-cancerous cells, and RNA and DNA analysis; Scientific research for medical purposes in the area of cancerous diseases; Advice on scientific information relating to alleviation, diagnosis, prevention and treatment of cancer; Administration of research, namely, scientific research in the fields of health, diet, nutrition, cancer and cancer prevention; Biological, scientific and oncological research laboratories services; Preparation of biological samples for testing and analysis in research laboratories, namely, research services in the field of forensic science in the nature of analysis, detection and isolation of biological substances in forensic samples; Provision of information and data relating to medical and veterinary research and development; all of the aforesaid services provided in relation to cancer diagnosis, treatment and therapy

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 6, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 6, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 22, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 15, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 14, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 14, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 14, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 1, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 30, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 30, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 30, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 19, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 19, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 19, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 10, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2025 CRFA
ASSIGNED TO LIE
Jun 10, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 2, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 21, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
May 21, 2025 GNSL
SUSPENSION LETTER WRITTEN
May 21, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2025 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 24, 2025 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 8, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 7, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 5, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 5, 2025 NWOS
NEW APPLICATION ENTERED
Oct 1, 2024 NWAP